European Countries Urged To Boost OTC Profile In Health Care Systems
This article was originally published in The Tan Sheet
Executive Summary
EU Health Commissioner John Dalli expects the region’s growing health care budgets and economic crisis to lead governments to restructure and impose more responsibility on consumers for health care costs. A self-medication working group launched in France will look at easing Rx-to-OTC switches.
You may also be interested in...
European Pharmacovigilance Update Still Causing Concern
The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.
Switch Obstacles In Europe Threaten OTC Industry Growth – GSK Exec
European perceptions that OTC status increases safety risks hinders switch applications, GSK exec Scarlett-Smith contends. He argues OTC buyers are health conscious, adverse events are not isolated to OTCs and despite the centralized switch process, members retain decentralized OTC policies.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.